Literature DB >> 24054399

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

Bryan D Choi1, Carter M Suryadevara2, Patrick C Gedeon3, James E Herndon4, Luis Sanchez-Perez2, Darell D Bigner5, John H Sampson6.   

Abstract

Chimeric antigen receptors (CAR)-transduced T cells hold great promise in the treatment of malignant disease. Here, we demonstrate that intracerebral injection with a human, epidermal growth factor receptor variant III (EGFRvIII)-specific, third generation CAR successfully treats glioma in mice. Importantly, these results endorse clinical translation of this CAR in patients with EGFRvIII-expressing brain tumors.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Central nervous system neoplasms; Epidermal growth factor receptor; Glioblastoma; Immunotherapy; T-lymphocytes

Mesh：

Substances：

Year:  2013        PMID： 24054399      PMCID： PMC3867597          DOI： 10.1016/j.jocn.2013.03.012

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN： 0967-5868            Impact factor:   1.961


  9 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Authors:  Renier Brentjens; Raymond Yeh; Yvette Bernal; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

3.  Long-term survival of patients with glioblastoma multiforme (GBM).

Authors:  Nicolas R Smoll; Karl Schaller; Oliver P Gautschi
Journal:  J Clin Neurosci       Date:  2013-01-23       Impact factor: 1.961

4.  Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.

Authors:  Masasuke Ohno; Atsushi Natsume; Ken Ichiro Iwami; Hidetaka Iwamizu; Kana Noritake; Daiki Ito; Yuki Toi; Motokazu Ito; Kazuya Motomura; Jun Yoshida; Kazuhiro Yoshikawa; Toshihiko Wakabayashi
Journal:  Cancer Sci       Date:  2010-09-30       Impact factor: 6.716

5.  Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Authors:  Richard A Morgan; Laura A Johnson; Jeremy L Davis; Zhili Zheng; Kevin D Woolard; Elizabeth A Reap; Steven A Feldman; Nachimuthu Chinnasamy; Chien-Tsun Kuan; Hua Song; Wei Zhang; Howard A Fine; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2012-09-24       Impact factor: 5.695

6.  Genetically engineered T cells to target EGFRvIII expressing glioblastoma.

Authors:  Szofia S Bullain; Ayguen Sahin; Oszkar Szentirmai; Carlos Sanchez; Ning Lin; Elizabeth Baratta; Peter Waterman; Ralph Weissleder; Richard C Mulligan; Bob S Carter
Journal:  J Neurooncol       Date:  2009-04-23       Impact factor: 4.130

7.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Authors:  Michael C Milone; Jonathan D Fish; Carmine Carpenito; Richard G Carroll; Gwendolyn K Binder; David Teachey; Minu Samanta; Mehdi Lakhal; Brian Gloss; Gwenn Danet-Desnoyers; Dario Campana; James L Riley; Stephan A Grupp; Carl H June
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

8.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

Authors:  R Nishikawa; X D Ji; R C Harmon; C S Lazar; G N Gill; W K Cavenee; H J Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

Review 9.  EGFRvIII-targeted vaccination therapy of malignant glioma.

Authors:  Bryan D Choi; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Roger E McLendon; Darell D Bigner; John H Sampson
Journal:  Brain Pathol       Date:  2009-10       Impact factor: 6.508
  9 in total
  39 in total

Review 1.  Diffuse intrinsic pontine glioma: time for therapeutic optimism.

Authors:  Soumen Khatua; Wafik Zaky
Journal:  CNS Oncol       Date:  2014

Review 2.  Epidermal growth factor receptor and variant III targeted immunotherapy.

Authors:  Kendra L Congdon; Patrick C Gedeon; Carter M Suryadevara; Hillary G Caruso; Laurence J N Cooper; Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 3.  Prioritization schema for immunotherapy clinical trials in glioblastoma.

Authors:  Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 4.  Immunotherapy of Primary Brain Tumors: Facts and Hopes.

Authors:  Robin A Buerki; Zinal S Chheda; Hideho Okada
Journal:  Clin Cancer Res       Date:  2018-06-05       Impact factor: 12.531

5.  A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Authors:  Patrick C Gedeon; Teilo H Schaller; Satish K Chitneni; Bryan D Choi; Chien-Tsun Kuan; Carter M Suryadevara; David J Snyder; Robert J Schmittling; Scott E Szafranski; Xiuyu Cui; Patrick N Healy; James E Herndon; Roger E McLendon; Stephen T Keir; Gary E Archer; Elizabeth A Reap; Luis Sanchez-Perez; Darell D Bigner; John H Sampson
Journal:  Clin Cancer Res       Date:  2018-04-27       Impact factor: 12.531

6.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 7.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

Review 8.  The progress of immunotherapy for glioblastoma.

Authors:  Qiangyi Zhou; Yu Wang; Wenbin Ma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 9.  Immunotherapy in glioblastoma: emerging options in precision medicine.

Authors:  Tiffany R Hodges; Sherise D Ferguson; Amy B Heimberger
Journal:  CNS Oncol       Date:  2016-05-26

10.  Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.

Authors:  Ahmet F Atik; Carter M Suryadevara; Ryan M Schweller; Jennifer L West; Patrick Healy; James E Herndon Ii; Kendra L Congdon; Luis Sanchez-Perez; Roger E McLendon; Gerald E Archer; Peter Fecci; John H Sampson
Journal:  J Clin Neurosci       Date:  2018-07-21       Impact factor: 1.961
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.